Table 1:

Demographics, metabolizer status, and risperidone exposures in study cohort

	N=257
	n(%)
Age at commencement of risperidone (years), median (IQR)	8.3 (6.3-10.5)
Sex
Male	188 (73.2)
Female	69 (26.8)
Race
White	217 (84.4)
African-American	29 (11.3)
Asian/Pacific islander	5 (1.9)
Unknown	5 (1.9)
Native American	1 (0.4)
Ethnicity
Hispanic	6 (2.3)
Non-Hispanic	246 (95.7)
Unknown	5 (1.9)
Risperidone baseline dose in mg/day, median (IQR)	0.5 (0.5-1)
CYP2D6 metabolizer phenotype
Poor metabolizer	15 (5.8)
Intermediate metabolizer	18 (7)
Normal metabolizer	218 (84.8)
Ultrarapid metabolizer	6 (2.3)

IQR – Interquartile Range